Aspire Biopharma Strengthens Team with New Appointment

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) has announced the addition of Dr. Mark J. Jaroszeski to its scientific team. Dr. Jaroszeski, a professor in the Department of Medical Engineering at the University of South Florida, is renowned for his contributions to DNA and drug delivery innovations. His expertise is expected to bolster Aspire's efforts in refining its proprietary sublingual delivery technology.

Interim CEO Kraig Higginson expressed the company's excitement, emphasizing Dr. Jaroszeski's role in advancing their drug delivery systems. Holding a PhD in Engineering Science, Dr. Jaroszeski's extensive background includes pioneering work in electroporation techniques and substantial contributions to clinical trials through his 34 U.S. patents.

Currently, he also serves as Vice President of Research at EF Therapeutics, Inc. With over two decades of experience, his appointment aims to enhance Aspire's efforts in developing efficient sublingual drug delivery methods.